Health Condition 1: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Indian Association of Dermatologists Venereologists and Leprologists
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 years or older who are willing to provide informed consent to participate in the study. 2. Individuals with a confirmed diagnosis of psoriasis vulgaris, whether previously diagnosed or newly diagnosed.
Exclusion criteria
Exclusion criteria: 1. Patients with a clinical diagnosis of palmoplantar psoriasis, pustular psoriasis, or erythrodermic psoriasis 2. Patients who are obese (BMI 30 kg/m2 or higher) 3. Patients who have used topical medications in the past 2 weeks, systemic therapy in the past 4 weeks, or biologic therapy in the past 8 weeks 4. Pregnancy or lactation 5. Patients with other existing dermatological conditions, including mycosis fungoides, hidradenitis suppurativa, atopic dermatitis, contact dermatitis, and cutaneous leishmaniasis 6. Patients with a history of systemic infections or active inflammatory conditions, including pneumonia, liver disease, tuberculosis, sarcoidosis, infectious mononucleosis, rheumatoid arthritis, malignancies, and autoimmune connective tissue diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the serum levels of adenosine deaminase and high sensitivity C-reactive protein in individuals diagnosed with psoriasis vulgaris and evaluate their correlation with disease severity.Timepoint: Serum ADA and hs-CRP levels will be estimated after completing data collection from all enrolled patients. Until then, blood samples will be stored under appropriate conditions in the institutional lab. Assay kits will be procured just before analysis, approximately 6 months after sample collection begins. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the correlation between ADA, hsCRP levels, & the severity of psoriasis vulgaris, as measured by the Psoriasis Area & Severity Index (PASI) score.Timepoint: To evaluate the correlation between ADA, hsCRP levels, & the severity of psoriasis vulgaris, as measured by the Psoriasis Area & Severity Index (PASI) score which will be done after data analysis, approximately 1 year from intitation of sample collection. | — |
Countries
India
Contacts
Public ContactShivashankara AR
Father Muller Medical College Hospital
Outcome results
None listed